Observation on the therapeutic effect of Lingze tablets in the treatment of patients with benign prostatic hyperplasia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045691

Enrollment

Unknown

Registered

2021-04-23

Start date

2021-05-01

Completion date

Unknown

Last updated

2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia

Interventions

Treatment group:Lingze tablet

Eligibility

Sex/Gender

Male

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. 45 years = 3 points; 4. B-ultrasound examination: around the eyes, the volume reaches more than 20ml; 5. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Residual urine > 100mL; 2. Difficulty urinating or frequent urination caused by other causes such as neurogenic bladder, bladder neck fibrosis, urethral stricture, etc.; 3. Repeated urinary retention (cannot urinate after extubation at least once or urinary retention twice); 4. Secondary upper urinary tract hydrops; 5. Allergic physique and a history of severe drug allergy; 6. Suffer from mental illness.

Design outcomes

Primary

Measure	Time frame
International Prostate Symptom Score;Qualty of Life;Overactive Bladder Symptom Scores;	—

Secondary

Measure	Time frame
volume of prostate;Residual urine volume;Urine flow rate;International Index of Erectile Function;Prostate specific antigen;Likert Scale;Overactive Bladder Symptom Scores;	—

Countries

China

Contacts

Public ContactWang Bin

Dongzhimen Hospital, Beijing University of Chinese Medicine

1028bj@sina.com+86 17812165002

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026